Cancer Clinical Trial - ImmuneSensor IMSA101-101

Cancer

Status:

Open

ClinicalTrials.gov:

NCT04020185

CONDITIONS(S): Advanced Solid Tumors - TRIAL: ImmuneSensor IMSA101-101-Safety and Efficacy Study of IMSA101 in Refractory Malignancies.

Open-label, dose escalation (Phase I) and dose expansion (Phase IIA) study of patients receiving intra-tumoral IMSA101 alone or in combination with an immune checkpoint inhibitor (ICI) (Phase I and II).

Drug

IMSA101; Immune checkpoint inhibitor (ICI); Immuno-oncology (IO) therapy

Trial Type

Interventional

Phase

Phase 1

Condition

Advanced solid tumors

Keywords